Reportedly cut 65% of its workforce and paused a clinical trial.
SourcePersonalized drug discovery for blood cancer.
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Notable Labs was a Foster City, California–based clinical-stage platform therapeutics company focused on predictive precision medicine for hematologic cancers. Its main platform, PPMP, used ex vivo testing plus software/automation to predict which drug or drug-combination was most likely to work for a given patient. The company later entered Chapter 7 bankruptcy in October 2024 and its assets were slated for liquidation.
Primary product
Predictive Precision Medicines Platform (PPMP)
Founded
2014
Headquarters
320 Hatch Dr, Foster City, California 94404, USA
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Clinical-stage platform therapeutics / precision oncology
Offices
Business model
Stage
public
Total raised
$72.2M
Latest round
Private placement / pre-merger financing · Oct 2023
Latest amount
$10.3M
Private placement / pre-merger financing
Oct 2023 · Builders VC
Jul 2019 · B Capital Group and LifeForce Capital
Sep 2017 · Builders VC
Jan 2014
Leadership
Chief Executive Officer (former; Feb 2021-Aug 2024)
Chief Scientific Officer (former; through Oct 2024)
Interim Chief Executive Officer & Chief Restructuring Officer (former; Sep 2024-Mar 2025)
Founders
Founder; former CEO / Executive Chairman
Co-founder; former COO/CFO/board member
Founder; Chief Operating Officer; Chief Financial Officer; Board Member
Investors
Mission-driven and science-focused; the company publicly emphasized 'mission over ego,' scientific responsibility, perseverance with compassion, relentless resourcefulness, respect, safety, and inclusivity.
Compensation
No public salary bands or compensation details were found in accessible sources; public job listings were visible but did not expose pay ranges.
Differentiators
Technology
Customers
Competitors
Estimated revenue
US$1M-$10M
Estimated monthly visits
131
Reportedly cut 65% of its workforce and paused a clinical trial.
SourceFiled for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware; assets to be liquidated and board/executives departed.
SourceExternal coverage confirmed the bankruptcy and stated that development of the Boehringer Ingelheim-licensed volasertib program was ending.
SourceNasdaq delisting determination became final; shares were removed from listing effective March 17, 2025.
SourceFierce Biotech · Oct 2024
Reported Chapter 7 bankruptcy, liquidation plans, and the end of the volasertib program.
San Francisco Business Times · Sep 2024
Reported 65% layoffs and a paused clinical trial amid financial strain.
SEC filing · Sep 2024
Board approved a streamlined operating plan, paused Phase 2 volasertib work, and cut workforce/consultants by about 65%.
Nasdaq / GlobeNewswire · Aug 2024
Thomas A. Bock resigned as CEO and board member; Joseph Wagner was named interim CEO.
BioSpace / GlobeNewswire · Jul 2024
FDA clearance and dosing-plan agreement moved the company's Phase 2 volasertib study for relapsed/refractory AML toward enrollment.